MY132006A
(en)
|
2000-05-26 |
2007-09-28 |
Schering Corp |
ADENOSINE A2a RECEPTOR ANTAGONISTS
|
GB0100624D0
(en)
*
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VII
|
IL160307A0
(en)
|
2001-08-31 |
2004-07-25 |
Univ Rockefeller |
Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
|
US20040110826A1
(en)
*
|
2001-09-28 |
2004-06-10 |
Noriaki Uesaka |
Receptor Antagonists
|
MXPA04003474A
(es)
|
2001-10-15 |
2004-07-30 |
Schering Corp |
Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a.
|
ATE358130T1
(de)
|
2001-11-30 |
2007-04-15 |
Schering Corp |
Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
|
MXPA04005209A
(es)
|
2001-11-30 |
2004-08-19 |
Schering Corp |
Antagonistas del receptor de adenosina a2a.
|
AR038366A1
(es)
|
2001-11-30 |
2005-01-12 |
Schering Corp |
Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
|
US6897217B2
(en)
|
2003-04-23 |
2005-05-24 |
Schering Corporation |
2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
|
WO2005103055A1
(en)
|
2004-04-21 |
2005-11-03 |
Schering Corporation |
PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
|
WO2006133261A2
(en)
|
2005-06-06 |
2006-12-14 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
ATE538123T1
(de)
|
2005-09-19 |
2012-01-15 |
Schering Corp |
2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
|
AR056080A1
(es)
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
JP5453086B2
(ja)
|
2006-06-06 |
2014-03-26 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
WO2008063505A1
(en)
|
2006-11-13 |
2008-05-29 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
WO2008070095A1
(en)
|
2006-12-05 |
2008-06-12 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
US7723343B2
(en)
|
2007-03-30 |
2010-05-25 |
King Pharmaceuticals Research And Development, Inc. |
Adenosine A2A receptor antagonists
|
EP2240490B1
(en)
|
2007-12-06 |
2013-09-04 |
Takeda Pharmaceutical Company Limited |
Organic compounds
|
KR20100094551A
(ko)
|
2007-12-06 |
2010-08-26 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
EP2262811B1
(en)
|
2008-03-04 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
|
WO2010009190A1
(en)
*
|
2008-07-16 |
2010-01-21 |
King Pharmaceuticals Research And Development, Inc. |
Methods of treating atherosclerosis
|
MX2011005935A
(es)
|
2008-12-06 |
2011-12-16 |
Intra Cellular Therapies Inc |
Compuestos organicos.
|
PE20120209A1
(es)
|
2008-12-06 |
2012-03-18 |
Intra Cellular Therapies Inc |
DERIVADOS DE IMIDAZO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA O PIRIMIDO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
|
EA201170773A1
(ru)
|
2008-12-06 |
2012-01-30 |
Интра-Селлулар Терапиз, Инк. |
Органические соединения
|
EP2367430B1
(en)
|
2008-12-06 |
2014-08-13 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
WO2010065148A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
SG171775A1
(en)
|
2008-12-06 |
2011-07-28 |
Intra Cellular Therapies Inc |
Organic compounds
|
EP2400970A4
(en)
|
2009-02-25 |
2012-07-18 |
Intra Cellular Therapies Inc |
PDE-1-HEMMER FOR EYE DRESSING
|
WO2010132127A1
(en)
|
2009-05-13 |
2010-11-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
SG178279A1
(en)
|
2009-08-05 |
2012-03-29 |
Intra Cellular Therapies Inc |
Novel regulatory proteins and inhibitors
|
WO2011153136A1
(en)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP2576551A4
(en)
|
2010-05-31 |
2014-04-16 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
EP2590657A4
(en)
|
2010-05-31 |
2014-02-12 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
US10561656B2
(en)
|
2011-06-10 |
2020-02-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
WO2014101120A1
(en)
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
US9801882B2
(en)
|
2013-02-17 |
2017-10-31 |
Intra-Cellular Therapies, Inc. |
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
|
PL2970279T3
(pl)
|
2013-03-15 |
2021-05-31 |
Intra-Cellular Therapies, Inc. |
Związki organiczne
|
EP2968338B1
(en)
|
2013-03-15 |
2019-01-09 |
Intra-Cellular Therapies, Inc. |
Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
|
WO2015106032A1
(en)
|
2014-01-08 |
2015-07-16 |
Intra-Cellular Therapies, Inc. |
Products and pharmaceutical compositions
|
EP3157926B1
(en)
|
2014-06-20 |
2019-05-15 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
DK3177627T3
(da)
|
2014-08-07 |
2019-10-21 |
Intra Cellular Therapies Inc |
Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
ES2915200T3
(es)
|
2014-09-17 |
2022-06-21 |
Intra Cellular Therapies Inc |
Derivados de 7,8-dihidro-[2H]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5H)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
|
CA2967944C
(en)
|
2014-11-18 |
2020-11-17 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with a2a antagonist properties
|
CN107205999B
(zh)
|
2014-12-06 |
2021-08-03 |
细胞内治疗公司 |
有机化合物
|
JP6608933B2
(ja)
|
2014-12-06 |
2019-11-20 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
US10138212B2
(en)
|
2015-02-06 |
2018-11-27 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as A2A antagonist
|
WO2016200717A1
(en)
|
2015-06-11 |
2016-12-15 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with a2a antagonist properties
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
JP7134168B6
(ja)
|
2016-09-12 |
2024-02-02 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
WO2019118313A1
(en)
|
2017-12-13 |
2019-06-20 |
Merck Sharp & Dohme Corp. |
Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
CN111072676B
(zh)
*
|
2019-12-12 |
2021-07-16 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|
US12364695B2
(en)
|
2020-06-02 |
2025-07-22 |
Intra-Cellular Therapies, Inc. |
Methods of treating inflammatory disease
|